Andrew Allen
About Andrew Allen
Andrew Allen is a Senior Scientist at Neumora and has over 13 years of experience in molecular and cell biology. He has held various research roles, including Senior Research Associate II at the Broad Institute and Lead Research Associate at Dana-Farber Cancer Institute, and focuses on developing therapeutics for neuropsychiatric diseases.
Current Role at Broad Institute
Andrew Allen serves as a Senior Research Associate II at the Broad Institute in Cambridge, Massachusetts. He has held this position since 2014, contributing to various research initiatives for a decade. His work focuses on molecular and cell biology, with an emphasis on developing therapeutics aimed at neuropsychiatric diseases.
Previous Experience in Research
Prior to his current role, Andrew Allen worked at Dana-Farber Cancer Institute as a Lead Research Associate from 2012 to 2014. He also held positions at Massachusetts General Hospital as a Research Tech I-II from 2009 to 2012, and at Jnana Therapeutics and Monte Rosa Therapeutics as Scientist I from 2018 to 2020. His diverse experience spans over 13 years in both academic and industrial settings.
Educational Background
Andrew Allen earned a Bachelor of Science (BS) in Biochemistry and Molecular Biology from UMass Amherst, completing his studies from 2004 to 2008. He continued his education at the same institution, obtaining a Master of Science (M.S.) in the same field from 2008 to 2009. His educational background provides a strong foundation for his research in molecular and cell biology.
Focus on Drug Discovery
Andrew Allen specializes in high-throughput in vitro assay development for early drug discovery. His research aims to develop therapeutics that significantly improve patient lives, particularly for those suffering from neuropsychiatric diseases. This focus aligns with his extensive experience in molecular biology and his commitment to advancing therapeutic options.